Show simple item record

dc.contributor.authorPeñalver, Francisco‐Javier
dc.contributor.authorMárquez, José‐Antonio
dc.contributor.authorDurán, Soledad
dc.contributor.authorGiraldo, Pilar
dc.contributor.authorMartín, Alejandro
dc.contributor.authorMontalbán, Carlos
dc.contributor.authorSancho, Juan-Manuel
dc.contributor.authorRamírez, María José
dc.contributor.authorTerol, María José
dc.contributor.authorCapote Huelva, Francisco Javier 
dc.contributor.authorGutiérrez, Antonio
dc.contributor.authorSánchez, Blanca
dc.contributor.authorLópez, Andrés
dc.contributor.authorSalar, Antonio
dc.contributor.authorRodríguez‐Caravaca, Gil
dc.contributor.authorCanales, Miguel
dc.contributor.authorCaballero, María‐Dolores
dc.contributor.authorGELTAMO (The Spanish Lymphoma Cooperative Group)
dc.date.accessioned2019-10-22T08:25:20Z
dc.date.available2019-10-22T08:25:20Z
dc.date.issued2019-10
dc.identifier.issn2045-7634
dc.identifier.urihttp://hdl.handle.net/10498/21839
dc.description.abstractBackground: Consensus is lacking regarding the optimal salvage therapy for patients with follicular lymphoma who relapse after or are refractory to immunochemotherapy. Methods: This phase II trial evaluated the efficacy and safety of response‐adapted therapy with rituximab, bendamustine, mitoxantrone, and dexamethasone (RBMD) in follicular lymphoma patients who relapsed after or were refractory to first‐line immunochemotherapy. Sixty patients received three treatment cycles, and depending on their response received an additional one (complete/unconfirmed complete response) or three (partial response) cycles. Patients who responded to induction received rituximab maintenance therapy for 2 years. Results: Thirty‐three (55%) and 42 (70%) patients achieved complete/unconfirmed complete response after three cycles and on completing induction therapy (4‐6 cycles), respectively (final overall response rate, 88.3%). Median progression‐free survival was 56.4 months (median follow‐up, 28.3 months; 95% CI, 15.6‐51.2). Overall survival was not reached. Progression‐free survival did not differ between patients who received four vs six cycles (P = .6665), nor between patients who did/did not receive rituximab maintenance after first‐line therapy (P = .5790). Median progression‐ free survival in the 10 refractory patients was 25.5 months (95% CI, 0.6‐N/A) and was longer in patients who had shown progression of disease after 24 months of first‐line therapy (median, 56.4 months; 95% CI, 19.8‐56.4) than in those who showed early progression (median, 42.31 months; 95% CI, 24.41–NA) (P = .4258). Thirty‐six (60%) patients had grade 3/4 neutropenia. Grade 3/4 febrile neutropenia and infection were recorded during induction (4/60 [6.7%] and 5/60 [8.3%] patients, respectively) and maintenance (2/43 [4.5%] and 4/43 [9.1%] patients, respectively). Conclusions: This response‐adapted treatment with RBMD followed by rituximab maintenance is an effective and well‐tolerated salvage treatment for relapsed/refractory follicular lymphoma following first‐line immunochemotherapy. Clinical trial registration: ClinicalTrials.gov # NCT01133158.en_US
dc.formatapplication/pdfen_US
dc.language.isoengen_US
dc.publisherWILEYen_US
dc.rightsAtribución 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.sourceCancer Medicine. 2019;00:1–13.en_US
dc.subjectbendamustineen_US
dc.subjectfollicular lymphomaen_US
dc.subjectimmunochemotherapyen_US
dc.subjectrefractoryen_US
dc.subjectrelapseden_US
dc.titleResponse‐adapted treatment with rituximab, bendamustine, mitoxantrone, and dexamethasone followed by rituximab maintenance in patients with relapsed or refractory follicular lymphoma after first‐line immunochemotherapy: Results of the RBMDGELTAMO08 phase II trialen_US
dc.typejournal articleen_US
dc.rights.accessRightsopen accessen_US
dc.identifier.doi10.1002/cam4.2555


Files in this item

This item appears in the following Collection(s)

Show simple item record

Atribución 4.0 Internacional
This work is under a Creative Commons License Atribución 4.0 Internacional